comparemela.com

Page 4 - Idorsia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Idorsia Shares Plunge After Suspension of 2025 Profitability Target

GNW-Adhoc: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - July 20, 2023 Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex-China) region ("Territory"), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in .

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

10.07.2023 - Ad hoc announcement pursuant to Art. 53 LR The approximately 20 million US lives covered by CVS will now have easier and more affordable access to QUVIVIQ Allschwil, Switzerland & Radnor, PA, United States – July 10, 2023Idorsia Ltd (SIX: . Seite 1

Idorsia (OTCMKTS:IDRSF) Earns Sell Rating from Analysts at Citigroup

Citigroup began coverage on shares of Idorsia (OTCMKTS:IDRSF – Free Report) in a report issued on Thursday morning, FlyOnTheWall reports. The firm issued a sell rating on the stock. Several other research firms also recently weighed in on IDRSF. Morgan Stanley assumed coverage on shares of Idorsia in a report on Thursday, June 22nd. They […]

GNW-Adhoc: Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - June 06, 2023 Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party regarding its operating businesses in the Asia Pacific (ex-China) region, including selected licens.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.